智通财经APP获悉,华源证券发布研报称,小核酸药物作为新一代疗法,凭借其靶向精准、药效持久及可作用于传统不可成药靶点等核心优势,市场进入高速成长期。行业在GalNAc等递送技术推动下已实现肝靶向药物的商业化突破,并逐步向心血管、中枢神经系统等常见病领域拓展。全球市场呈现“一超多强”格局,龙头企业Alnylam商业化表现突出,研发管线密集且BD交易活跃,推动行业持续扩容。华源证券主要观点如下:小核酸...
Source Link智通财经APP获悉,华源证券发布研报称,小核酸药物作为新一代疗法,凭借其靶向精准、药效持久及可作用于传统不可成药靶点等核心优势,市场进入高速成长期。行业在GalNAc等递送技术推动下已实现肝靶向药物的商业化突破,并逐步向心血管、中枢神经系统等常见病领域拓展。全球市场呈现“一超多强”格局,龙头企业Alnylam商业化表现突出,研发管线密集且BD交易活跃,推动行业持续扩容。华源证券主要观点如下:小核酸...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.